Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CarbSlim is a dietary supplement designed for weight management and carbohydrate control, primarily marketed by HealthAid. Its active ingredient is white kidney bean extract (*Phaseolus vulgaris*), often utilizing the proprietary Phase 2 Carb Controller formulation. The supplement functions as a carbohydrate blocker by inhibiting the enzyme alpha-amylase in the digestive tract. Alpha-amylase is responsible for the breakdown of complex starches into simple, absorbable sugars; by blocking this process, CarbSlim reduces the caloric absorption from starchy foods and may assist in weight loss and glycemic control. It is typically administered orally in capsule form and is categorized as a nutraceutical rather than a pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CarbSlim.